You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

 

Online download statistics by month:

Online download statistics by month: August 2022 to March 2026

AbstractFullPdf
Aug 2022554564163
Sep 2022643654259
Oct 2022347350103
Nov 202219319585
Dec 202222822980
Jan 202316116145
Feb 202315415564
Mar 202314114261
Apr 2023969746
May 2023979848
Jun 2023929440
Jul 202310110156
Aug 202314814850
Sep 202310610730
Oct 202322122147
Nov 202310510654
Dec 2023949547
Jan 2024808159
Feb 2024818148
Mar 2024959572
Apr 2024879068
May 2024858754
Jun 2024636456
Jul 202410810942
Aug 2024848446
Sep 2024767744
Oct 2024767640
Nov 202420620745
Dec 20249910150
Jan 2025979836
Feb 2025929347
Mar 202510910952
Apr 202513813873
May 2025737444
Jun 2025575939
Jul 2025110
Sep 2025110
Mar 2026110
Total519052432193